文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

中年HIV感染者接受良好cART后沉默性小血管病患病率是未感染者的两倍

Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals.
PubMed 文献 · Clin Infect Dis · 2018-01-01

法国MicroBREAK横断面研究纳入456例病毒载量控制≥12个月、≥50岁的经治HIV感染者(PLHIV)和154例年龄性别匹配的未感染对照,用3T MRI评估沉默性脑小血管病(CSVD)。PLHIV中CSVD占51.5%,对照占36.4%,校正传统危险因素后aOR为2.3;HIV影响随年龄而异,<54岁aOR 5.3、54-60岁3.7、>60岁1.0(P=.022)。

要点

  • 中年经治PLHIV的CSVD患病率约为未感染者的2倍(51.5% vs 36.4%)。
  • HIV对CSVD的影响在较年轻组更显著,<54岁aOR达5.3。
  • PLHIV中年龄较大、高血压和较低CD4最低值是CSVD独立相关因素。

核心结论

  • HIV是CSVD的独立危险因素,即使免疫病毒学控制良好,中年PLHIV的CSVD患病率仍约为未感染者的两倍。

研究设计与样本

  • ANRS EP51 MicroBREAK(NCT02082574)为横断面研究,前瞻性纳入456例≥50岁、病毒载量控制≥12个月的经治PLHIV和154例年龄性别频数匹配的HIV未感染对照。
  • 由2名盲法神经放射科医生在3T MRI上诊断CSVD,采用logistic回归校正传统危险因素评估HIV影响。

主要发现

  • PLHIV中CSVD检出率为51.5%,HIV未感染对照为36.4%,校正后OR为2.3。
  • HIV对CSVD的影响随年龄不同:<54岁、54-60岁、>60岁的aOR分别为5.3、3.7、1.0(P=.022)。
  • PLHIV中年龄较大、高血压和较低CD4细胞最低值与CSVD风险升高独立相关。
  • PLHIV与对照的中位年龄分别为56岁和58岁(P=.001),男性比例分别为84.9%和77.3%(P=.030)。

临床怎么用

  • 对中年PLHIV应关注沉默性脑小血管病风险,尤其在较年轻组和合并高血压、CD4最低值较低者中。
  • 即使病毒载量控制良好,仍需将脑血管病风险评估纳入常规随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Silent cerebral small-vessel disease (CSVD) is defined as white matter hyperintensities, silent brain infarction, or microbleeds. CSVD is responsible for future vascular events, cognitive impairment, frailty, and shorter survival. CSVD prevalence among middle-aged people living with well-controlled human immunodeficiency virus (HIV) infection (PLHIV) is unknown. METHODS: The French National Agency for Research on AIDS and Viral Hepatitis (ANRS) EP51 Microvascular Brain Retina and Kidney Study (MicroBREAK; NCT02082574) is a cross-sectional study with prospective enrollment of treated PLHIV, ≥50 years old with viral load controlled for ≥12 months, and frequency age- and sex-matched HIV-uninfected controls (HUCs). It was designed to estimate CSVD prevalence on 3T magnetic resonance imaging (3D fluid-attenuated inversion recovery, transversal T2-weighted gradient-echo imaging and diffusion-weighted imaging), as diagnosed by 2 blinded neuroradiologists. A logistic regression model was used to assess the impact of HIV on CSVD after adjustment for traditional risk factors. RESULTS: Between June 2013 and May 2016, 456 PLHIV and 154 HUCs were recruited. Median age was 56 and 58 years, respectively (P = .001), among whom 84.9% and 77.3%, respectively (P = .030), were men. CSVD was detected in 51.5% of PLHIV and 36.4% of HUCs with an adjusted odds ratio (aOR) of 2.3. The HIV impact differed according to age, with aOR values of 5.3, 3.7, and 1.0 for age groups <54, 54-60, and >60 years, respectively (P = .022). Older age, hypertension, and lower CD4 cell count nadir were independently associated with a higher risk of CSVD among PLHIV. CONCLUSIONS: HIV is an independent risk factor for CSVD. Despite sustained immunovirological control, the CSVD prevalence was twice as high among middle-aged PLHIV than HUCs. CLINICAL TRIALS REGISTRATION: NCT02082574.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Moulignier A, Savatovsky J, Assoumou L, et al. Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals. Clin Infect Dis. 2018. PMID: 29244126. doi:10.1093/cid/cix1075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。